Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Structural progression of Alzheimer&apos, s disease over decades: the MRI staging scheme

  • Planche, Vincent
  • Mansecal, Boris
  • Lanuza, Enrique
  • Tourdias, Thomas
  • Catheline, Gwenaelle
  • Coupé, Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] The chronological progression of brain atrophy over decades, from pre-symptomatic to dementia stages, has never been formally depicted in Alzheimer's disease. This is mainly due to the lack of cohorts with long enough MRI follow-ups in cognitively unimpaired young participants at baseline. To describe a spatiotemporal atrophy staging of Alzheimer's disease at the whole-brain level, we built extrapolated lifetime volumetric models of healthy and Alzheimer's disease brain structures by combining multiple large-scale databases (n = 3512 quality controlled MRI from 9 cohorts of subjects covering the entire lifespan, including 415 MRI from ADNI1, ADNI2 and AIBL for Alzheimer's disease patients). Then, we validated dynamic models based on cross-sectional data using external longitudinal data. Finally, we assessed the sequential divergence between normal aging and Alzheimer's disease volumetric trajectories and described the following staging of brain atrophy progression in Alzheimer's disease: (i) hippocampus and amygdala; (ii) middle temporal gyrus; (iii) entorhinal cortex, parahippocampal cortex and other temporal areas; (iv) striatum and thalamus and (v) middle frontal, cingular, parietal, insular cortices and pallidum. We concluded that this MRI scheme of atrophy progression in Alzheimer's disease was close but did not entirely overlap with Braak staging of tauopathy, with a 'reverse chronology' between limbic and entorhinal stages. Alzheimer's disease structural progression may be associated with local tau accumulation but may also be related to axonal degeneration in remote sites and other limbic-predominant associated proteinopathies., This study was achieved within the context of the Human Brain Project, the French National Research Agency for the DeepvolBrain project (ANR-18-CE45-0013), the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project and the CNRS/INSERM for the DeepMultiBrain project. V.P. received grants from Foundation Bettencourt Schueller (CCA-Inserm-Bettencourt). J.V.M. research was supported by the Spanish DPI2017-87743-R grant from the Ministerio de Economia, Industria y Competitividad of Spain. The sponsors did not participate in any aspect of the design or performance of the study, including data collection, management, analysis, and the interpretation or preparation, review and approval of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Toward a unified analysis of cerebellum maturation and aging across the entire lifespan: A MRI analysis

  • Romero, José E.
  • Coupé, Pierrick
  • Lanuza, Enrique
  • Catheline, Gwenaelle
  • Alzheimers Disease Neuroimaging Initiative
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Previous literature about the structural characterization of the human cerebellum is related to the context of a specific pathology or focused in a restricted age range. In fact, studies about the cerebellum maturation across the lifespan are scarce and most of them considered the cerebellum as a whole without investigating each lobule. This lack of study can be explained by the lack of both accurate segmentation methods and data availability. Fortunately, during the last years, several cerebellum segmenta- tion methods have been developed and many databases comprising subjects of dif- ferent ages have been made publically available. This fact opens an opportunity window to obtain a more extensive analysis of the cerebellum maturation and aging. In this study, we have used a recent state-of-the-art cerebellum segmentation method called CERES and a large data set (N = 2,831 images) from healthy controls covering the entire lifespan to provide a model for 12 cerebellum structures (i.e., lob- ules I-II, III, IV, VI, Crus I, Crus II, VIIB, VIIIA, VIIIB, IX, and X). We found that lobules have generally an evolution that follows a trajectory composed by a fast growth and a slow degeneration having sometimes a plateau for absolute volumes, and a decreasing tendency (faster in early ages) for normalized volumes. Special consider- ation is dedicated to Crus II, where slow degeneration appears to stabilize in elder ages for absolute volumes, and to lobule X, which does not present any fast growth during childhood in absolute volumes and shows a slow growth for normalized volumes., Stavros Niarchos Foundation; University of California, Los Angeles; University of California, San Diego; Northern California Institute for Research and Education; Foundation for the National Institutes of Health; U.S. Food and Drug Administration; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; F. Hoffmann-La Roche; Novartis; Johnson & Johnson; GE Healthcare; Elan; Bristol-Myers Squibb; Bayer Schering; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health; Cincinnati Children's Hospital Medical Center; French National Research Agency, Grant/Award Number: CE45-0013
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

DeepCERES: A deep learning method for cerebellar lobule segmentation using ultra-high resolution multimodal MRI

  • Morell-Ortega, Sergio|||0009-0001-7639-2915
  • Vivó, Roberto|||0000-0002-0751-4114
  • Rubio Navarro, Gregorio
  • DE LA IGLESIA VAYÁ, MARIA DE LOS DESAMPARADOS
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Ruiz-Perez, Marina
  • Gadea, Marien
  • Aparici-Robles, Fernando
  • Catheline, Gwenaelle
  • Mansecal, Boris
  • Coupé, Pierrick
[EN] This paper introduces a novel multimodal and high-resolution human brain cerebellum lobule segmentation method. Unlike current tools that operate at standard resolution (1 mm3 ) or using mono-modal data, the proposed method improves cerebellum lobule segmentation through the use of a multimodal and ultra-high resolution (0.125 mm3 ) training dataset. To develop the method, first, a database of semi-automatically labelled cerebellum lobules was created to train the proposed method with ultra-high resolution T1 and T2 MR images. Then, an ensemble of deep networks has been designed and developed, allowing the proposed method to excel in the complex cerebellum lobule segmentation task, improving precision while being memory efficient. Notably, our approach deviates from the traditional U-Net model by exploring alternative architectures. We have also integrated deep learning with classical machine learning methods incorporating a priori knowledge from multi-atlas segmentation which improved precision and robustness. Finally, a new online pipeline, named DeepCERES, has been developed to make available the proposed method to the scientific community requiring as input only a single T1 MR image at standard resolution., This work has been developed thanks to the project PID2020-118608RB-I00 and to the project PID2023-152127OB-I00 of the Ministerio de Ciencia, Innovacion y Universidades de España. This work also benefited from the support of the project DeepvolBrain and HoliBrain of the French National Research Agency (ANR-18-CE45-0013 and ANR23-CE45-0020-01). This study was achieved within the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10- IDEX- 03- 02, HL-MRI Project), Cluster of excellence CPU and the CNRS.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

DeepLesionBrain: Towards a broader deep-learning generalization for multiple sclerosis lesion segmentation

  • Kamraoui, Reda Abdellah
  • Ta, Vinh-Thong
  • Tourdias, Thomas
  • Mansencal, Boris
  • Coupé, Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Recently, segmentation methods based on Convolutional Neural Networks (CNNs) showed promising per-formance in automatic Multiple Sclerosis (MS) lesions segmentation. These techniques have even out-performed human experts in controlled evaluation conditions such as Longitudinal MS Lesion Segmenta-tion Challenge (ISBI Challenge). However, state-of-the-art approaches trained to perform well on highly-controlled datasets fail to generalize on clinical data from unseen datasets. Instead of proposing another improvement of the segmentation accuracy, we propose a novel method robust to domain shift and per-forming well on unseen datasets, called DeepLesionBrain (DLB). This generalization property results from three main contributions. First, DLB is based on a large group of compact 3D CNNs. This spatially dis-tributed strategy aims to produce a robust prediction despite the risk of generalization failure of some individual networks. Second, we propose a hierarchical specialization learning (HSL) by pre-training a generic network over the whole brain, before using its weights as initialization to locally specialized net-works. By this end, DLB learns both generic features extracted at global image level and specific features extracted at local image level. Finally, DLB includes a new image quality data augmentation to reduce dependency to training data specificity (e.g., acquisition protocol). DLB generalization was validated in cross-dataset experiments on MSSEG'16, ISBI challenge, and in-house datasets. During experiments, DLB showed higher segmentation accuracy, better segmentation consistency and greater generalization per-formance compared to state-of-the-art methods. Therefore, DLB offers a robust framework well-suited for clinical practice. (c) 2021 Published by Elsevier B.V., This work benefited from the support of the project Deep-volBrain of the French National Research Agency (ANR-18-CE45-0013) . This study was achieved within the context of the Labo-ratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project) , Clus-ter of excellence CPU and the CNRS/INSERM for the DeepMulti-Brain project. This study has also been supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria Competitividad. The authors gratefully acknowledge the support of NVIDIA Corporation with their donation of the TITAN Xp GPU used in this research.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Ultra-high resolution multimodal MRI densely labelled holistic structural brain atlas

  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Morell-Ortega, Sergio|||0009-0001-7639-2915
  • Rubio Navarro, Gregorio
  • Ruiz-Perez, Marina
  • Mansecal, Boris
  • Le Bot, Edern
  • Gadea, Marien
  • Lanuza, Enrique
  • Catheline, Gwenaelle
  • Tourdias, Thomas
  • Planche, Vicent
  • Giraud, Rémi
  • Rivière, Denis
  • Mangin, Jean-Francois
  • Labra-Avila, Nicole
  • Vivo-Hernando, Roberto
  • Aparici-Robles, Fernando
  • de la Iglesia-Vaya, María
  • Coupé, Pierrick
[EN] In this paper, we introduce a novel structural holistic Atlas (holiAtlas) of human brain anatomy based on multimodal and high-resolution MRI that covers several anatomical levels from the organ level to the substructure level, using a new protocol for dense labelling generated from the fusion of multiple local protocols at different scales. This atlas was constructed by averaging images and segmentations of 75 healthy subjects from the Human Connectome Project database. Specifically, 3T MR images of T1, T2 and WMn (White Matter nulled) contrasts at 0.125 mm3 resolution were selected for this project. The images of these 75 subjects were nonlinearly registered and averaged using symmetric group-wise normalisation to construct the atlas. At the finest level, the proposed atlas has 350 different labels derived from 7 distinct delineation protocols. These labels were grouped at multiple scales, offering a coherent and consistent holistic representation of the brain across different levels of detail. This multiscale and multimodal atlas can be used to develop new ultra-high-resolution segmentation methods, potentially improving the early detection of neurological disorders. We make it publicly available to the scientific community., This work has been developed thanks to the projects PID2020-118608RB-I00 and PID2023-152127OB-I00 of the Ministerio de Ciencia e Innovacion de España. This work also benefited from the support of the projects DeepvolBrain, HoliBrain and FOLDDICO of the French National Research Agency (ANR-18-CE45-0013, ANR-23-CE45-0020-01 and ANR-20-CHIA-0027- 01). Finally, this study received financial support from the French government in the framework of the University of Bordeaux's France 2030 program / RRI "IMPACT, the PEPR StratifyAging and the IHU VBHI (ANR-23-IAHU-0001). We thank the support of ITACA (Institute of Information and Communication Technologies) at UPV (Universitat Politècnica de València).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Lifespan Changes of the Human Brain In Alzheimer&apos, s Disease

  • Coupé, Pierrick
  • Lanuza, Enrique
  • Catheline, Gwenaelle
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Brain imaging studies have shown that slow and progressive cerebral atrophy characterized the development of Alzheimer's Disease (AD). Despite a large number of studies dedicated to AD, key questions about the lifespan evolution of AD biomarkers remain open. When does the AD model diverge from the normal aging model? What is the lifespan trajectory of imaging biomarkers for AD? How do the trajectories of biomarkers in AD differ from normal aging? To answer these questions, we proposed an innovative way by inferring brain structure model across the entire lifespan using a massive number of MRI (N = 4329). We compared the normal model based on 2944 control subjects with the pathological model based on 3262 patients (AD + Mild cognitive Impaired subjects) older than 55 years and controls younger than 55 years. Our study provides evidences of early divergence of the AD models from the normal aging trajectory before 40 years for the hippocampus, followed by the lateral ventricles and the amygdala around 40 years. Moreover, our lifespan model reveals the evolution of these biomarkers and suggests close abnormality evolution for the hippocampus and the amygdala, whereas trajectory of ventricular enlargement appears to follow an inverted U-shape. Finally, our models indicate that medial temporal lobe atrophy and ventricular enlargement are two mid-life physiopathological events characterizing AD brain., This work benefited from the support of the project DeepVolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX- 03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria y Competitividad. Moreover, this work is based on multiple samples. We wish to thank all investigators of these projects who collected these datasets and made them freely accessible. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). A listing of the participating sites and a complete listing of the study investigators can be found at https://research.cchmc.org/c-mind. The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). NDAR is a collaborative informatics system created by the National Institutes of Health to provide a national resource to support and accelerate research in autism. The NDAR dataset includes data from the NIH Pediatric MRI Data Repository created by the NIH MRI Study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Differential annualized rates of hippocampal subfields atrophy in aging and future Alzheimer&apos, s clinical syndrome

  • Nadal, Louis
  • Coupé, Pierrick
  • Helmer, Catherine
  • Amieva, Helene
  • Tison, François
  • Dartigues, Jean-François
  • Catheline, Gwenaelle
  • Planche, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Several studies have investigated the differential vulnerability of hippocampal subfields during aging and Alzheimer's disease (AD). Results were often contradictory, mainly because these works were based on concatenations of cross-sectional measures in cohorts with different ages or stages of AD, in the absence of a longitudinal design. Here, we investigated 327 participants from a population-based cohort of nondemented older adults with a 14-year clinical follow-up. MRI at baseline and 4 years later were assessed to measure the annualized rates of hippocampal subfields atrophy in each participant using an automatic segmentation pipeline with subsequent quality control. On the one hand, CA4 dentate gyrus was significantly more affected than the other subfields in the whole population (CA1-3: -0.68%/year; subiculum: -0.99%/year; and CA4-DG: -1.39%/year; p < 0.0001). On the other hand, the annualized rate of CA1-3 atrophy was associated with an increased risk of developing Alzheimer's clinical syndrome over time, independently of age, gender, educational level, and ApoE4 genotype (HR = 2.0; CI 95% 1.4-3.0). These results illustrate the natural history of hippocampal subfields atrophy during aging and AD by showing that the dentate gyrus is the most vulnerable subfield to the effects of aging while the cornu-ammonis is the primary target of AD pathophysiological processes, years before symptom onset., The 3C Study is conducted under a partnership agreement among the Institut National de la Sante et de la Recherche Medicale (INSERM), Bordeaux University, and Sanofi. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study is also supported by Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, Mutuelle Generale de l'Education Nationale, Institut de la Longevite, Conseils Regionaux d'Aquitaine et Bourgogne, Fondation de France, and the Ministry of Research-INSERM Programme "Cohortes et collections de donnees biologiques". The follow-ups have also been funded by ANR 2007LVIE 003, the "Fondation Plan Alzheimer," and the Caisse Nationale de Solidarite pour l'Autonomie (CNSA). This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013) and by the Spanish DPI2017-87743-R grant from the Ministerio de Economia, Industria y Competitividad of Spain. In addition, this study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Finally, the authors thank the Investments for the future Program IdEx Bordeaux (ANR10-IDEX-03-02, HL-MRI Project), Cluster of excellence CPU, and the CNRS. VP also received grants from Fondation Bettencourt Schueller (CCA-Inserm-Bettencourt). The sponsors did not participate in any aspect of the design or performance of the study, including data collection, management, analysis, and the interpretation or preparation, review, and approval of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

pBrain: A novel pipeline for Parkinson related brain structure segmentation

  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Vivó, Roberto|||0000-0002-0751-4114
  • Bertó, Alexa
  • Romero, José E.
  • Lanuza, Enrique
  • Aparici-Robles, Fernando
  • Coupé, Pierrick
[EN] Parkinson is a very prevalent neurodegenerative disease impacting the life of millions of people worldwide. Although its cause remains unknown, its functional and structural analysis is fundamental to advance in the search of a cure or symptomatic treatment. The automatic segmentation of deep brain structures related to Parkinson's disease could be beneficial for the follow up and treatment planning. Unfortunately, there is not broadly available segmentation software to automatically measure Parkinson related structures. In this paper, we present a novel pipeline to segment three deep brain structures related to Parkinson's disease (substantia nigra, subthalamic nucleus and red nucleus). The proposed method is based on the multi-atlas label fusion technology that works on standard and high-resolution T2-weighted images. The proposed method also includes as post-processing a new neural network-based error correction step to minimize systematic segmentation errors. The proposed method has been compared to other state-of-the-art methods showing competitive results in terms of accuracy and execution time., The authors want to thank Dr. Mallar Chakravarty for making accessible the HR MRI data used in the proposed pipeline. This research was supported by the Spanish DPI2017-87743-R grant from the Ministerio de Economia, Industria y Competitividad of Spain. This work also benefited from the support of the project DeepVolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models

  • Coupé, Pierrick
  • Mansencal, Boris
  • Tourdias, Thomas
  • Catheline, Gwenaelle
  • Planche, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] In this article, we present an innovative MRI-based method for Alzheimer disease (AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan trajectories of brain structures. After a full screening of the most discriminant structures between AD and normal aging based on MRI volumetric analysis of 3,032 subjects, we propose a novel Hippocampal-Amygdalo-Ventricular Atrophy score (HAVAs) based on normative lifespan models and AD lifespan models. During a validation on three external datasets on 1,039 subjects, our approach showed very accurate detection (AUC >= 94%) of patients with AD compared to control subjects and accurate discrimination (AUC = 78%) between progressive MCI and stable MCI (during a 3-year follow-up). Compared to normative modeling, classical machine learning methods and recent state-of-the-art deep learning methods, our method demonstrated better classification performance. Moreover, HAVAs simplicity makes it fully understandable and thus well-suited for clinical practice or future pharmaceutical trials., UK Alzheimer's Society, Grant/Award Number: RF116; GlaxoSmithKline, Grant/Award Number: 6GKC; Leon Levy Foundation; NIMH, Grant/Award Numbers: R03MH096321, K23MH087770; ABIDE; U.K. Engineering and Physical Sciences Research Council, Grant/Award Number: GR/S21533/02; Canadian Institutes of Health Research, Grant/Award Number: MOP-34996; Human Brain Project, Grant/Award Number: PO1MHO52176-11; Alzheimer Drug Discovery Foundation; Alzheimer Association; National Health and Medical Research Council of Australia, Grant/Award Number: 1011689; Science Industry Endowment Fund; Common-wealth Scientific Industrial Research Organization; OASIS Brains Datasets, Grant/Award Numbers: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584; NIH, Grant/Award Numbers: K01 AG030514, P30AG010129; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; National Institutes of Health, Grant/Award Number: U01 AG024904; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Institute on Drug Abuse; National Institute of Child Health and Human Development, Grant/Award Number: HHSN275200900018C; Ministerio de Ciencia e Innovacion, Grant/Award Number: PID2020-118608RB-I00; French National Research Agency, Grant/Award Number: ANR-18-CE45-0013
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Longitudinal detection of new MS lesions using deep learning

  • Kamraoui, Reda Abdellah
  • Mansecal, Boris
  • Coupé, Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] The detection of new multiple sclerosis (MS) lesions is an important marker of the evolution of the disease. The applicability of learning-based methods could automate this task e ciently. However, the lack of annotated longitudinal data with new-appearing lesions is a limiting factor for the training of robust and generalizing models. In this study, we describe a deep-learning-based pipeline addressing the challenging task of detecting and segmenting new MS lesions. First, we propose to use transfer-learning from a model trained on a segmentation task using single time-points. Therefore, we exploit knowledge from an easier task and for which more annotated datasets are available. Second, we propose a data synthesis strategy to generate realistic longitudinal time-points with new lesions using single time-point scans. In this way, we pretrain our detection model on large synthetic annotated datasets. Finally, we use a data-augmentation technique designed to simulate data diversity in MRI. By doing that, we increase the size of the available small annotated longitudinal datasets. Our ablation study showed that each contribution lead to an enhancement of the segmentation accuracy. Using the proposed pipeline, we obtained the best score for the segmentation and the detection of new MS lesions in the MSSEG2 MICCAI challenge., This study benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02 and RRI IMPACT), the French Ministry of Education and Research, and the CNRS for the DeepMultiBrain project. This study has also been supported by the PID2020-118608RB-I00 grants from the Spanish Ministerio de Economia, Industria Competitividad.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

AssemblyNet: A large ensemble of CNNs for 3D whole brain MRI segmentation

  • Coupé, Pierrick
  • Mansencal, Boris
  • Clement, Michael
  • Giraud, Rémi
  • Denis de Senneville, Baudouin
  • Ta, Vinh-Thong
  • Lepetit, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Whole brain segmentation of fine-grained structures using deep learning (DL) is a very challenging task since the number of anatomical labels is very high compared to the number of available training images. To address this problem, previous DL methods proposed to use a single convolution neural network (CNN) or few independent CNNs. In this paper, we present a novel ensemble method based on a large number of CNNs processing different overlapping brain areas. Inspired by parliamentary decision-making systems, we propose a framework called AssemblyNet, made of two "assemblies" of U-Nets. Such a parliamentary system is capable of dealing with complex decisions, unseen problem and reaching a relevant consensus. AssemblyNet introduces sharing of knowledge among neighboring U-Nets, an "amendment" procedure made by the second assembly at higher-resolution to refine the decision taken by the first one, and a final decision obtained by majority voting. During our validation, AssemblyNet showed competitive performance compared to state-of-the-art methods such as U-Net, Joint label fusion and SLANT. Moreover, we investigated the scan-rescan consistency and the robustness to disease effects of our method. These experiences demonstrated the reliability of AssemblyNet. Finally, we showed the interest of using semi-supervised learning to improve the performance of our method., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-0 3-02, HL-MRI Project), Cluster of excellence CPU and the CNRS/INSERM for the DeepMultiBrain project. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria Competitividad. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation. The OASIS data used in the preparation of this manuscript were obtained from the OASIS project funded by grants P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584. The AIBL data used in the preparation of this manuscript were obtained from the AIBL study of ageing funded by the Common-wealth Scientific Industrial Research Organization (CSIRO; a publicly funded government research organization), Science Industry Endowment Fund, National Health and Medical Research Council of Australia (project grant 1011689), Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation. The ICBM data used in the preparation of this manuscript were supported by Human Brain Project grant PO1MHO52176-11 (ICBM, P.I. Dr John Mazziotta) and Canadian Institutes of Health Research grant MOP-34996. The IXI data used in the preparation of this manuscript were supported by the U.K. Engineering and Physical Sciences Research Council (EPSRC) GR/S21533/02. ABIDE primary support for the work by Adriana Di Martino was provided by the NIMH (K23MH087770) and the Leon Levy Foundation. Primary support for the work by Michael P. Milham and the INDI team was provided by gifts from Joseph P. Healy and the Stavros Niarchos Foundation to the Child Mind Institute, as well as by an NIMH award to MPM (R03MH096321).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

vol2Brain: A New Online Pipeline for Whole Brain MRI Analysis

  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Vivó, Roberto|||0000-0002-0751-4114
  • Rubio Navarro, Gregorio
  • DE LA IGLESIA VAYÁ, MARIA DE LOS DESAMPARADOS
  • Romero, José E.
  • Aparici, Fernando
  • Coupé, Pierrick
[EN] Automatic and reliable quantitative tools for MR brain image analysis are a very valuable resource for both clinical and research environments. In the past few years, this field has experienced many advances with successful techniques based on label fusion and more recently deep learning. However, few of them have been specifically designed to provide a dense anatomical labeling at the multiscale level and to deal with brain anatomical alterations such as white matter lesions (WML). In this work, we present a fully automatic pipeline (vol2Brain) for whole brain segmentation and analysis, which densely labels (N > 100) the brain while being robust to the presence of WML. This new pipeline is an evolution of our previous volBrain pipeline that extends significantly the number of regions that can be analyzed. Our proposed method is based on a fast and multiscale multi-atlas label fusion technology with systematic error correction able to provide accurate volumetric information in a few minutes. We have deployed our new pipeline within our platform volBrain (), which has been already demonstrated to be an efficient and effective way to share our technology with the users worldwide., This research was supported by the Spanish DPI2017-87743-R grant from the Ministerio de Economia, Industria y Competitividad of Spain. This work was benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

RegQCNET: Deep quality control for image-to-template brain MRI affine registration

  • Denis de Senneville, Baudouin
  • Coupé, Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Affine registration of one or several brain image(s) onto a common reference space is a necessary prerequisite for many image processing tasks, such as brain segmentation or functional analysis. Manual assessment of registration quality is a tedious and time-consuming task, especially in studies comprising a large amount of data. Automated and reliable quality control (QC) becomes mandatory. Moreover, the computation time of the QC must be also compatible with the processing of massive datasets. Therefore, automated deep neural network approaches have emerged as a method of choice to automatically assess registration quality. In the current study, a compact 3D convolutional neural network, referred to as RegQCNET, is introduced to quantitatively predict the amplitude of an affine registration mismatch between a registered image and a reference template. This quantitative estimation of registration error is expressed using the metric unit system. Therefore, a meaningful task-specific threshold can be manually or automatically defined in order to distinguish between usable and non-usable images. The robustness of the proposed RegQCNET is first analyzed on lifespan brain images undergoing various simulated spatial transformations and intensity variations between training and testing. Secondly, the potential of RegQCNET to classify images as usable or non-usable is evaluated using both manual and automatic thresholds. During our experiments, automatic thresholds are estimated using several computer-assisted classification models (logistic regression, support vector machine, Naive Bayes and random forest) through cross-validation. To this end we use an expert's visual QC estimated on a lifespan cohort of 3953 brains. Finally, the RegQCNET accuracy is compared to usual image features such as image correlation coefficient and mutual information. The results show that the proposed deep learning QC is robust, fast and accurate at estimating affine registration error in the processing pipeline., The experiments presented in this paper were carried out using the PlaFRIM experimental testbed, supported by Inria, CNRS (LABRI and IMB), Universite de Bordeaux, Bordeaux INP and Conseil Regional d'Aquitaine (see https://www.plafrim.fr/). This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the Future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project), the Cluster of Excellence CPU and the CNRS/INSERM for the DeepMultiBrain project. This study has been also supported by a DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria Competitividad. The authors gratefully acknowledge the support of NVIDIA Corporation with their donation of a TITAN X GPU used in this research.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Lifespan neurodegeneration of the human brain in multiple sclerosis

  • Coupé, Pierrick
  • Planche, Vicent
  • Mansecal, Boris
  • Kamroui, Reda A.
  • Koubiyr, Ismail
  • Tourdias, Thomas
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Spatiotemporal progression of the MS-related atrophy. Progression of MS-related atrophy along the three axes with radiological convention for all the structures.image, French National Research Agency, Grant/Award Number: ANR-18-CE45-0013;Laboratory of Excellence TRAIL, Grant/Award Number: ANR-10-LABX-57; IdEx Bordeaux, Grant/Award Number: ANR-10-IDEX-03-02;French Ministry of Education and Research; Centre national de la recherche scientifique; Spanish Ministerio de Ciencia e Innovacion, Grant/Award Number: PID2020-118608RB-I00; University of Bordeaux's France 2030 program/RRI "IMPACT"
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Multi-scale graph-based grading for Alzheimer&apos, s disease prediction

  • Hett, Kilian
  • Ta, Vinh-Thong
  • Oguz, Ipek
  • Coupé, Pierrick
  • Alzheimers Disease Neuroimaging Initiative
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] The prediction of subjects with mild cognitive impairment (MCI) who will progress to Alzheimer¿s disease (AD) is clinically relevant, and may above all have a significant impact on accelerating the development of new treatments. In this paper, we present a new MRI-based biomarker that enables us to accurately predict conversion of MCI subjects to AD. In order to better capture the AD signature, we introduce two main contributions. First, we present a new graph-based grading framework to combine inter-subject similarity features and intra-subject variability features. This framework involves patch-based grading of anatomical structures and graph-based modeling of structure alteration relationships. Second, we propose an innovative multiscale brain analysis to capture alterations caused by AD at different anatomical levels. Based on a cascade of classifiers, this multiscale approach enables the analysis of alterations of whole brain structures and hippocampus subfields at the same time. During our experiments using the ADNI-1 dataset, the proposed multiscale graph-based grading method obtained an area under the curve (AUC) of 81% to predict conversion of MCI subjects to AD within three years. Moreover, when combined with cognitive scores, the proposed method obtained 85% of AUC. These results are competitive in comparison to state-of-the-art methods evaluated on the same dataset., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE450013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. Finally, this work was also supported by the NIH grants R01-NS094456 and U01-NS106845. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01-AG024904) and by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Biogen; Bristol-Myes Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffman-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Pharmaceutical Research & Development LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute of Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries

  • Pin, Grégoire
  • Coupé, Pierrick
  • Nadal, Louis
  • Helmer, Catherine
  • Amieva, Helene
  • Mazoyer, Bernard
  • Dartigues, Jean-François
  • Catheline, Gwenaelle
  • Planche, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Background and Purpose: Many neurological or psychiatric diseases affect the hippocampus during aging. The study of hippocampal regional vulnerability may provide important insights into the pathophysiological mechanisms underlying these processes; however, little is known about the specific impact of vascular brain damage on hippocampal subfields atrophy. Methods: To analyze the effect of vascular injuries independently of other pathological conditions, we studied a population-based cohort of nondemented older adults, after the exclusion of people who were diagnosed with neurodegenerative diseases during the 14-year clinical follow-up period. Using an automated segmentation pipeline, 1.5T-magnetic resonance imaging at inclusion and 4 years later were assessed to measure both white matter hyperintensities and hippocampal subfields volume. Annualized rates of white matter hyperintensity progression and annualized rates of hippocampal subfields atrophy were then estimated in each participant. Results: We included 249 participants in our analyses (58% women, mean age 71.8, median Mini-Mental State Evaluation 29). The volume of the subiculum at baseline was the only hippocampal subfield volume associated with total, deep/subcortical, and periventricular white matter hyperintensity volumes, independently of demographic variables and vascular risk factors (ß=¿0.17, P=0.011; ß=¿0.25, P=0.020 and ß=¿0.14, P=0.029, respectively). In longitudinal measures, the annualized rate of subiculum atrophy was significantly higher in people with the highest rate of deep/subcortical white matter hyperintensity progression, independently of confounding factors (ß=¿0.32, P=0.014). Conclusions: These cross-sectional and longitudinal findings highlight the links between vascular brain injuries and a differential vulnerability of the subiculum within the hippocampal loop, unbiased of the effect of neurodegenerative diseases, and particularly when vascular injuries affect deep/subcortical structures., The 3C Study is conducted under a partnership agreement among the Institut National de la Sante et de la Recherche Medicale (INSERM), Bordeaux University, and Sanofi. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study is also supported by Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, Mutuelle Generale de l'Education Nationale, Institut de la Longevite, Conseils Regionaux d'Aquitaine et Bourgogne, Fondation de France, and the Ministry of Research-INSERM Programme "Cohortes et collections de donnees biologiques". The followups have also been funded by ANR 2007LVIE 003, the "Fondation Plan Alzheimer" and the Caisse Nationale de Solidarite pour l'Autonomie (CNSA). This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013) and by the Spanish DPI2017-87743-R grant from the Ministerio de Economia, Industria y Competitividad of Spain. In addition, this study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Finally, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. VP also received grants from Fondation Bettencourt Schueller (CCA-Inserm-Bettencourt) during the conduct of the study but unrelated to the present work. The sponsors did not participate in any aspect of the design or performance of the study, including data collection, management, analysis, and the interpretation or preparation, review, and approval of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Anatomical MRI staging of frontotemporal dementia variants

  • Planche, Vicent
  • Mansecal, Boris
  • Tourdias, Thomas
  • Catheline, Gwenaelle
  • Coupé, Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] INTRODUCTIONThe three clinical variants of frontotemporal dementia (behavioral variant [bvFTD], semantic dementia, and progressive non-fluent aphasia [PNFA]) are likely to develop over decades, from the preclinical stage to death. METHODSTo describe the long-term chronological anatomical progression of FTD variants, we built lifespan brain charts of normal aging and FTD variants by combining 8022 quality-controlled MRIs from multiple large-scale data-bases, including 107 bvFTD, 44 semantic dementia, and 38 PNFA. RESULTSWe report in this manuscript the anatomical MRI staging schemes of the three FTD variants by describing the sequential divergence of volumetric trajectories between normal aging and FTD variants. Subcortical atrophy precedes focal cortical atrophy in specific behavioral and/or language networks, with a "radiological" prodromal phase lasting 8-10 years (time elapsed between the first structural alteration and canonical cortical atrophy). DISCUSSIONAmygdalar and striatal atrophy can be candidate biomarkers for future preclinical/prodromal FTD variants definitions. HighlightsWe describe the chronological MRI staging of the most affected structures in the three frontotemporal dementia (FTD) syndromic variants.In behavioral variant of FTD (bvFTD): bilateral amygdalar, striatal, and insular atrophy precedes fronto-temporal atrophy.In semantic dementia: bilateral amygdalar atrophy precedes left temporal and hippocampal atrophy.In progressive non-fluent aphasia (PNFA): left striatal, insular, and thalamic atrophy precedes opercular atrophy., French National Research Agency (ANR-18-CE45-0013); Laboratory of Excellence TRAIL ANR-10-LABX-57; Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02 and RRI "IMPACT"); Spanish Ministerio de Ciencia e innovacion (PID2020-118608RB-I00)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis

  • Koubiyr, Ismail
  • Yamamoto, Takayuki
  • Blyau, Simon
  • Kamroui, Reda A.
  • Mansecal, Boris
  • Planche, Vicent
  • Petit, Laurent
  • Saranathan, Manojkumar
  • Casey, Roman
  • Ruet, Aurélie
  • Brochet, Bruno
  • Dousset, Vincent
  • Coupé, Pierrick
  • Tourdias, Thomas
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Background and ObjectivesThalamic atrophy can be used as a proxy for neurodegeneration in multiple sclerosis (MS). Some data point toward thalamic nuclei that could be affected more than others. However, the dynamic of their changes during MS evolution and the mechanisms driving their differential alterations are still uncertain.MethodsWe paired a large cohort of 1,123 patients with MS with the same number of healthy controls, all scanned with conventional 3D-T1 MRI. To highlight the main atrophic regions at the thalamic nuclei level, we validated a segmentation strategy consisting of deep learning-based synthesis of sequences, which were used for automatic multiatlas segmentation. Then, through a lifespan-based approach, we could model the dynamics of the 4 main thalamic nuclei groups.ResultsAll analyses converged toward a higher rate of atrophy for the posterior and medial groups compared with the anterior and lateral groups. We also demonstrated that focal MS white matter lesions were associated with atrophy of groups of nuclei when specifically located within the associated thalamocortical projections. The volumes of the most affected posterior group, but also of the anterior group, were better associated with clinical disability than the volume of the whole thalamus.DiscussionThese findings point toward the thalamic nuclei adjacent to the third ventricle as more susceptible to neurodegeneration during the entire course of MS through potentiation of disconnection effects by regional factors. Because this information can be obtained even from standard T1-weighted MRI, this paves the way toward such an approach for future monitoring of patients with MS., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. This study received financial support from the French government in the framework of the University of Bordeaux's France 2030 program/RRI "IMPACT". Moreover, the authors thank the French Ministry of Education and Research, and the CNRS for DeepMultiBrain project. This study has also been supported by the PID2020-118608RB-I00 grant from the Spanish Ministerio de Ciencia e Innovacion. The MS data collection has been supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "France 2030" programme, under the reference ANR-10-COHO-002, Observatoire Francais de la Sclerose en Plaques (OFSEP)" and "Eugene Devic EDMUS Foundation against multiple sclerosis".
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Multimodal Hippocampal Subfield Grading For Alzheimer&apos, s Disease Classification

  • Hett, Kilian
  • Ta, Vinh-Thong
  • Catheline, Gwenaelle
  • Tourdias, Thomas
  • Coupé, Pierrick
  • Alzheimers Disease Neuroimaging Initiative
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Numerous studies have proposed biomarkers based on magnetic resonance imaging (MRI) to detect and predict the risk of evolution toward Alzheimer's disease (AD). Most of these methods have focused on the hippocampus, which is known to be one of the earliest structures impacted by the disease. To date, patch-based grading approaches provide among the best biomarkers based on the hippocampus. However, this structure is complex and is divided into different subfields, not equally impacted by AD. Former in-vivo imaging studies mainly investigated structural alterations of these subfields using volumetric measurements and microstructural modifications with mean diffusivity measurements. The aim of our work is to improve the current classification performances based on the hippocampus with a new multimodal patch-based framework combining structural and diffusivity MRI. The combination of these two MRI modalities enables the capture of subtle structural and microstructural alterations. Moreover, we propose to study the efficiency of this new framework applied to the hippocampal subfields. To this end, we compare the classification accuracy provided by the different hippocampal subfields using volume, mean diffusivity, and our novel multimodal patch-based grading framework combining structural and diffusion MRI. The experiments conducted in this work show that our new multimodal patch-based method applied to the whole hippocampus provides the most discriminating biomarker for advanced AD detection while our new framework applied into subiculum obtains the best results for AD prediction, improving by two percentage points the accuracy compared to the whole hippocampus., This study has been carried out with financial support from the French State, managed by the French National Research Agency (ANR) thanks to the funding of the project DeepvolBrain (ANR-18-CE45-0013) and in the frame of the Investments for the future Program IdEx Bordeaux, Cluster of excellence CPU and labex TRAIL (BigDataBrain ANR-10-LABX-57). The study presented in this work is a part of the thesis entitled "Multi-scale and multimodal imaging biomarkers for the early detection of Alzheimer's disease" defended by the same author. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Biogen; Bristol-Myes Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffman-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Pharmaceutical Research & Development LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute of Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.